fruquintinib + adebrelimab + oxaliplatin + capecitabine

This entry describes the combination of fruquintinib, adebrelimab, oxaliplatin, and capecitabine. Based on the provided search results: * Fruquintinib is described as a highly selective and potent oral inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2, and 3, approved for metastatic colorectal cancer. * Oxaliplatin and capecitabine (CAPOX/XELOX) is described as a chemotherapy combination used for colorectal cancer treatment. * Adebrelimab is not mentioned in the search results. * The specific four-drug combination of fruquintinib, adebrelimab, oxaliplatin, and capecitabine is not mentioned in the search results. Therefore, comprehensive information about this particular combination cannot be provided based solely on the given text. The combination may be experimental or in early clinical trials not covered by the provided information.